...
首页> 外文期刊>Aging and Disease >Pharmacological Treatment of Vascular Dementia: A Molecular Mechanism Perspective
【24h】

Pharmacological Treatment of Vascular Dementia: A Molecular Mechanism Perspective

机译:血管痴呆的药理治疗:分子机制的观点

获取原文

摘要

Vascular dementia (VaD) is a neurodegenerative disease, with cognitive dysfunction attributable to cerebrovascular factors. At present, it is the second most frequently occurring type of dementia in older adults (after Alzheimer's disease). The underlying etiology of VaD has not been completely elucidated, which limits its management. Currently, there are no approved standard treatments for VaD. The drugs used in VaD are only suitable for symptomatic treatment and cannot prevent or reduce the occurrence and progression of VaD. This review summarizes the current status of pharmacological treatment for VaD, from the perspective of the molecular mechanisms specified in various pathogenic hypotheses, including oxidative stress, the central cholinergic system, neuroinflammation, neuronal apoptosis, and synaptic plasticity. As VaD is a chronic cerebrovascular disease with multifactorial etiology, combined therapy, targeting multiple pathophysiological factors, may be the future trend in VaD.copyright: ? 2021 Kuang et al.
机译:血管性痴呆(VAD)是一种神经变性疾病,可归因于脑血管因子的认知功能障碍。目前,它是老年人(阿尔茨海默病后)中最常发生的痴呆症。 VAD的潜在病因尚未完全阐明,这限制了其管理。目前,VAD没有批准的标准治疗方法。 VAD中使用的药物仅适用于对症治疗,无法预防或减少VAD的发生和进展。本综述总结了VAD的药理治疗的现状,从各种致病假设中规定的分子机制的角度,包括氧化应激,中央胆碱能系统,神经炎症,神经细胞凋亡和突触可塑性。随着VAD是一种慢性脑血管疾病,具有多因素病因,组合治疗,靶向多种病理生理因素,可能是VAD.COPYRIGHT的未来趋势:? 2021 kuang等人。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号